Future use of bevacizumab and other anti-angiogenic agents in breast cancer
Future use of bevacizumab and other anti-angiogenic agents in breast cancer
复制标题
DOI：
10.1016/s1359-6349(08)70291-x
复制
发表时间：
2008-03-01
期刊：
影响因子：
--
通讯作者：
Bell, Richard
中科院分区：
文献类型：
--
作者：
Cameron, David;Bell, Richard
贝伐单抗是第一个用于治疗乳腺癌的商用血管生成抑制剂，在治疗这种疾病方面提供了显著的临床益处。当联合紫杉醇作为转移性乳腺癌的一线治疗时，与单独使用紫杉醇治疗相比，它显著提高了中位无进展生存率和1年生存率。此外，在更难治的晚期乳腺癌患者中，在卡培他滨的基础上加用贝伐单抗也被发现具有临床活性，显著提高了应答率，但不能延长无进展生存期。贝伐单抗的作用机制及其在晚期疾病中的临床活性均提示其在辅助和新辅助治疗中应发挥积极作用。抑制血管内皮生长因子应该会抑制手术后现有微转移的生长(辅助治疗)，并可以通过减小肿瘤大小来提高患者保乳的资格(新辅助治疗)。一项临床试验计划正在进行中，以评估贝伐单抗与其他抗癌药物在乳腺癌转移、辅助和新辅助治疗一线中的作用。(C)2008爱思唯尔有限公司。保留所有权利。
Bevacizumab, the first commercially available angiogenesis inhibitor for the treatment of breast cancer, offers significant clinical benefits in the management of this disease. When combined with paclitaxel as first-line treatment of metastatic breast cancer, it significantly increases both median progression-free survival and 1-year survival when compared with treatment with paclitaxel alone. Furthermore, the addition of bevacizumab to capecitabine in patients with more refractory advanced breast cancer was also found to be clinically active, significantly increasing response rate but not extending progression-free survival. Both the mechanism of action of bevacizumab and its clinical activity in advanced disease suggest that it should be active in adjuvant and neoadjuvant therapy. Inhibition of vascular endothelial growth factor should inhibit the growth of existing micrometastases following surgery (adjuvant therapy), and could enhance patient eligibility for breast conservation by decreasing tumour size (neoadjuvant therapy). A clinical trial programme is underway to evaluate the role of bevacizumab in combination with other anticancer agents in the first-line metastatic, adjuvant and neoadjuvant treatment of breast cancer. (C) 2008 Elsevier Ltd. All rights reserved.